Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report

Ascendis Pharma A/S Stock price

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 04:00:00 2023-09-29 pm EDT 		Intraday chart for Ascendis Pharma A/S 5-day change 1st Jan Change
93.64 USD -1.38% -1.49% -23.33%
Sep. 23 Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency CI
Sep. 21 Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower Thursday MT

Financials

Sales 2023 * 214 M 227 M Sales 2024 * 356 M 377 M Capitalization 5 052 M 5 356 M
Net income 2023 * -520 M -551 M Net income 2024 * -464 M -492 M EV / Sales 2023 *
24,3x
Net Debt 2023 * 150 M 159 M Net Debt 2024 * 241 M 256 M EV / Sales 2024 *
14,9x
P/E ratio 2023 *
-9,83x
P/E ratio 2024 *
-11,5x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float10.27%
More Fundamentals * Assessed data

Chart Ascendis Pharma A/S

Dynamic Chart

Latest news about Ascendis Pharma A/S

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency CI
Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower Thursday MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading MT
Ascendis Pharma Launches Skytrofa Growth Hormone in Germany MT
Constellation Software's Perseus Closes Purchase of Black Knight's Empower, Optimal Blue Businesses MT
Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency CI
Ascendis Pharma's TransCon PTH Receives Positive Opinion From European Regulator MT
Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism CI
European Equities Traded in the US as American Depositary Receipts Slightly Higher Wednesday MT
Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:55 PM CI
Prime Mining Corp. Announcing Expansion Drilling Results From the Z-T, Guadalupe and Central Zones at Los Reyes MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher Monday MT
Transcript : Ascendis Pharma A/S Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 02:40 PM CI
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating MT
More news

Analyst Recommendations on Ascendis Pharma A/S

Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating MT
Wedbush Raises Ascendis Pharma's Price Target to $192 From $187 After Model Adjustments, Keeps Outperform Rating MT
Wedbush Lifts Ascendis Pharma's Price Target to $187 From $186, Keeps Outperform Rating MT
Wedbush Lowers Ascendis Pharma's Price Target to $186 From $195 After Model Adjustments, Keeps Outperform Rating MT
Morgan Stanley Adjusts Ascendis Pharma's Price Target to $109 From $107, Keeps Equalweight Rating MT
More recommendations

Press releases Ascendis Pharma A/S

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency AQ
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency AQ
Ascendis Pharma Launches SKYTROFA in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency AQ
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency AQ
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism AQ
More press releases

News in other languages on Ascendis Pharma A/S

Ascendis Pharma A/S présente les résultats de l'essai à long terme enliGHten sur TransCon hGH dans le traitement du déficit en hormone de croissance chez l'enfant
Les valeurs pharmaceutiques sont en tête des actions européennes négociées aux Etats-Unis, les American Depositary Receipts étant en baisse jeudi
Les actions européennes négociées aux États-Unis sous forme de certificats américains d'actions étrangères (ADR) grimpent dans les échanges de mercredi
Ascendis Pharma lance SKYTROFA (lonapegsomatropine) en Allemagne pour le traitement hebdomadaire des enfants et des adolescents souffrant d'un déficit en hormone de croissance.
Ascendis Pharma A/S reçoit un avis positif du CHMP pour Transcon PTH (Palopegteriparatide) pour les adultes atteints d'hypoparathyroïdie chronique
More news

Quotes and Performance

1 day+0.42%
1 week-0.51%
Current month-3.13%
1 month-3.57%
3 months+9.16%
6 months-13.46%
Current year-22.25%
More quotes

Highs and lows

1 week
91.59
Extreme 91.585
96.68
1 month
91.59
Extreme 91.585
106.45
Current year
64.33
Extreme 64.33
127.77
1 year
64.33
Extreme 64.33
134.53
3 years
61.58
Extreme 61.5791
183.98
5 years
53.21
Extreme 53.205
183.98
10 years
11.92
Extreme 11.92
183.98
More quotes

Quotes

Date Price Change Volume
23-09-29 93.64 -1.38% 235 983
23-09-28 94.95 +0.94% 205,004
23-09-27 94.07 -0.15% 197,508
23-09-26 94.21 -1.35% 331,333
23-09-25 95.50 +0.46% 180,510

Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT

More quotes

Company Profile

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Sector
Biotechnology & Medical Research
Calendar
2023-11-28 - Q3 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Ascendis Pharma A/S

Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
89.86EUR
Average target price
132.91EUR
Spread / Average Target
+47.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi. (M$)
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
-22.25% 5 338 M $
VITASPRING BIOMEDICAL CO. LTD. Stock VitaSpring Biomedical Co. Ltd.
+4.17% 3 105 M $
SOLENO THERAPEUTICS, INC. Stock Soleno Therapeutics, Inc.
+1293.43% 358 M $
PROTEOMICS INTERNATIONAL LABORATORIES LIMITED Stock Proteomics International Laboratories Limited
+16.84% 71 M $
OLIPASS CORPORATION Stock OLIPASS Corporation
-47.70% 74 M $
RAYZEBIO, INC. Stock RayzeBio, Inc.
 0.00% 1 218 M $
INFLARX N.V. Stock InflaRx N.V.
-4.84% 174 M $
PYXIS ONCOLOGY, INC. Stock Pyxis Oncology, Inc.
+52.24% 89 M $
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. Stock ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
 0.00% 1 335 M $
VALBIOTIS Stock VALBIOTIS
+57.22% 67 M $
Bio Therapeutic Drugs
  1. Markets
  2. Equities
  3. Stock Ascendis Pharma A/S - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer